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Previewscontrol of excessive inflammation in the
gut. However, IL-10 is not simply a deac-
tivator of macrophage function. Alone
or combined with LPS, it activates tran-
scriptional programs related to the con-
trol and deactivation of immunity and
inflammation, remodeling of the extracel-
lular matrix, and B cell function (Manto-
vani et al., 2004). It will be important to
assess whether induction for instance of
increased mannose receptor expression
or selected chemokines plays a role in
the homeostatic functions of intestinal
macrophages.
Therapeutic approaches aimed at re-
storing gut homeostasis during inflam-
matory bowel disorders have been the
subject of intense experimentation. IL-10
therapy in IBD patients has not resulted
in substantial clinical improvements, sug-
gesting that more refined alternative ther-
apeutic strategies should be considered.Given the complexity of the mucosal
environment and the peculiarity of its
immune populations, better knowledge
of the networks regulating the delicate
intestinal balance is required to tailor
therapeutic strategies. The data pre-
sented here suggest that macrophages
might represent a prime target to control
inflammation in the gastrointestinal tract.REFERENCES
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Cytokines can provide survival and proliferation signals to cancer cells, thus promoting tumor progression.
In this issue of Immunity, Kryczek et al. (2014) reveal that interleukin-22 can also promote ‘‘stemness’’ in
human colorectal cancer via transcription factor STAT3-mediated epigenetic regulation of stem cell genes.Chronic inflammation facilitates cancer
development, as illustrated by the in-
creased incidence of colitis-associated
colon cancers (CAC) in patients with in-
flammatory bowel diseases (IBD) or liver
cancer in patients with hepatitis. Many
other cancers, including sporadic colo-
rectal cancer (CRC), do not initially arise
in an inflammatory context but later on
induce ‘‘tumor-elicited inflammation.’’
This inflammatory reaction acquired by
tumors is important, because nonspecific
inhibition of inflammation with aspirin
reduces cancer-related deaths, and high
interleukin-17 (IL-17) expression marks
CRC with poor prognosis (Tosolini et al.,2011). Proinflammatory cytokines, whose
expression is elevated in tumors, mediate
crosstalk between immune and cancer
cells. Receptors for such cytokines are
often expressed by epithelial cells and
are able to activate key transcription
factors, such as NF-kB and signal trans-
ducer and activator of transcription 3
(STAT3), that normally maintain tissue
homeostasis, but when deregulated can
contribute to malignant transformation.
The ability of cytokines to activate key
oncogenic signaling hubs has focused
research toward understanding their role
in promoting cell proliferation and survival
during tumorigenesis. In this issue ofImmunity, Kryczek et al. (2014) demon-
strate that IL-22 promotes human CRC
relying on STAT3-dependent pathway of
epigenetic activation of genes respon-
sible for maintenance of CRC cancer
stem cells, thus adding a new dimension
to what we know about how cytokines
promote cancer through other, potentially
diverse, mechanisms.
IL-22 has recently emerged as a key
regulator of epithelial homeostasis at
multiple organ sites, including skin, liver,
lung, and gastrointestinal tract. IL-22 trig-
gers phosphorylation and activation of
STAT3 to mediate its protective effects
on the intestinal epithelium during colitis40, May 15, 2014 ª2014 Elsevier Inc. 639
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Figure 1. IL-22-Mediated Mechanisms of Colon Cancer Development
IL-22, produced by Th22 and Th17 cells and by ILC, is a potent STAT3 activator in epithelial and cancer
cells. The IL-22-STAT3 pathway promotes expression of genes involved in cell proliferation, resistance to
cell death, tissue and resistance to infection and stresses, as well as various chemokines. This is required
for tissue homeostasis, protection, and regeneration but also can promote tumor initiation and growth.
Kryczek et al. now demonstrate that in CRC, activation of the IL-22-STAT3 pathway upregulates the his-
tone H3K79 dimethylase DOT1L, which is essential for STAT3-driven elevation of core genes involved in
cell ‘‘stemness.’’ Therefore, IL-22 also regulates the emergence of cancer stem cells in CRC via the
STAT3-DOT1L pathway to contribute to CRC tumorigenicity.
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Previews(Pickert et al., 2009), and IL-22-driven
STAT3 activation is detected in several
models of intestinal tumorigenesis and
is essential for tumor growth (Huber et al.,
2012; Kirchberger et al., 2013). The ability
of the IL-22-STAT3 pathway to induce the
expression of tissue protective genes,
such as antiapoptotic molecules, anti-
microbial peptides, and chemokines,
fits seemingly well into the accepted
dogma that IL-22, just like many other
cytokines, might directly regulate normal
and malignant cell survival and prolifera-
tion (Figure 1).
Kryczek et al. found that human CRC
tumors contained elevated amounts of
IL-22 compared with matching normal
tissue and that expression was also
high in tumor-infiltrating immune cells,
a many times seen ‘‘smoking gun’’ for
the potential involvement of a cytokine
in tumorigenesis. Indeed, in a model
where single cell suspensions of human
CRC tumors (containing both cancer
and immune cells) were injected into
immunodeficient mice, IL-22 enhanced640 Immunity 40, May 15, 2014 ª2014 Elsevitumorigenic potential of CRC cells
and IL-22 neutralization blocked tumor
growth. Treatment of CRC cells with
IL-22 predictably activated STAT3 but
surprisingly induced the expression of
bona fide stem cell markers, such as
SOX2, NANOG, and POU5F1 and also
promoted sphere formation in an in vitro
surrogate assay for stemness. STAT3 is
important regulator of the stem cell
compartment in a normal mouse intestine
(Matthews et al., 2011). Indeed, STAT3
was required for the IL-22 driven increase
in CRC stem cell numbers. Surprisingly,
IL-22 treatment of cells increased histone
3 lysine 79 dimethylation (H3K79me2)
and STAT3 was found to regulate the
expression of disruptor of telomeric
silencing-1 (DOT1L), the only H3K79
methyltransferase discovered so far,
and its histone binding cofactor AFF4.
DOT1L associated with the promoter
regions of ‘‘stemness’’ genes such as
Nanog, Sox2, and Pou5f and increased
their expression, therefore contributing
to enhancement of stem cell propertieser Inc.of cancer cells. Previous work suggested
that DOT1L deficiency abrogates cell
proliferation and indeed, knocking down
DOT1L blocked the IL-22-dependent in-
crease in CRC cancer stem cell numbers.
Finally, studies in CRC patients demon-
strated that IL-22, DOT1L, and SOX2
expression correlate with each other and
with poor survival (Kryczek et al., 2014).
Previous studies did not single out IL-
22 as a prognostic factor in CRC, but
indeed demonstrated that an increase
in expression of RORgt (required for
IL-22 expression) and IL-17A (often coex-
pressed with IL-22) correlates with bad
prognosis in human CRC (Tosolini et al.,
2011).
What is the source of IL-22 in human
CRC? IL-22 can be produced by innate
lymphoid cells (ILC) in IBD and in
CAC tumors of Rag2/ infected with
H. hepaticus and injected with AOM
(Kirchberger et al., 2013). Here, authors
found preferential accumulation of CD3+
CD4+IL-22+ cells, also expressing CCR6,
and RORgt, a phenotype characteristic
of memory helper T cells; in agreement
that in human CRC IL-22 is mostly pro-
duced by CD3+ T cells with a fraction of it
coming from ILC (Kirchberger et al.,
2013). Although these cells might repre-
sent the T helper 22 (Th22) cell subset,
up to 30% also expressed IL-17 (Kryczek
et al., 2014) and therefore could be
classified as ‘‘Th17 cells.’’ Functionally,
IL-22+ T cells were able to migrate into
CRC tumors and increase CRC ‘‘stem-
ness’’ in a coculture experiment, in a
largely IL-22-dependent manner (Kryczek
et al., 2014), confirming their protumori-
genic role. In CRC, STAT3 was often
shown tobehyperactivated at the invasive
front of the tumor, a site where potential
cancer stem cells might be located. It
still remains to be demonstrated whether
ILC and Th22 cells might have different
patterns of distribution in the tumor
(tumor-infiltrating versus peritumoral) and
that topology might better define their
respective roles in activation of STAT3-
dependent ‘‘bulk’’ tumor growth versus
STAT3-dependent promotion of ‘‘stem-
ness’’ phenotype and tumor progression.
Are other cytokines and transcription
factors involved in the promotion of
‘‘stemness’’ in cancer? The answer is yes,
because previous work demonstrated
that deregulated activation of NF-kB
rendered stem cells properties to
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Previewstransformed intestinal epithelial cells
(Schwitalla et al., 2013). Can other
STAT3-activating cytokines drive the
same pathway to ‘‘stemness’’ as IL-22
does? IL-6 and IL-11 were previously
shown to be important for CRC, parti-
cularly through their ability to activate
STAT3 (Putoczki et al., 2013). Although
IL-11 was not analyzed in the current
study, addition of IL-6 to CRC cell lines
elicited much weaker effect than the one
by IL-22 on sphere formation, although
no sIL-6R (normally available in tumor
microenvironment to mediate IL-6 trans-
signaling) were added to ensure full
sensitivity of CRCcells to IL-6. One impor-
tant quality of IL-22R over IL-6R and
IL-11R is that IL-22R signaling is
not subject to negative-feedback-loop
regulation by suppressor of cytokine
signaling 3 (SOCS3), which is a direct
STAT3 target. Indeed, this might give
significant advantages to the sustained
IL-22 dependent protumorigenic sig-
naling, although SOCS3 is often mutated
or downregulated by epigenetic mecha-
nisms in CRC. Another possible diver-
gence between IL-22 and IL-6 and IL-11
might lie in the identity of cytokine-pro-
ducing cells and in intricacies of cytokine
gene regulation. For example, production
of IL-6 and IL-11 by myeloid cells even in
the presence of abundant stimuli (i.e.,
Toll-like receptor ligands) can be halted
with time due to the phenomenon of
‘‘LPS tolerance,’’ whereas production of
IL-22 by ILC and Th22 cells might be
sustainable as long as tumor-specific
stimuli are present.
Previous studies pointed out a sig-
nificant role of ‘‘cancer stem cells’’ in
resistance of tumors to conventional
therapies. It will be exciting to find out
whether the activation status of com-
ponents of IL-22-STAT3-DOT1L pathway
is anyhow predictive of poor response
to therapy and, vice versa, whether
their inhibition could provide significant
improvements of current chemothera-peutic regimens. Similarly, as increased
IL-22 production correlates with poor
prognosis in CRC, it is also important
to explore whether ‘‘IL-22 high’’ patients
should get DOT1L inhibitors, selected
for more sophisticated chemotherapies,
or treated with IL-22 blockers prior or
past surgery.
An essential question is what are the
host and environmental cues that deter-
mine ‘‘high’’ or ‘‘low’’ IL-22 expression
profile? Likely, genetics will play some
role, and indeed distinct polymorphisms
in IL-22 promoter are linked with CRC
risk (Kryczek et al., 2014). However, it is
also known that the expression of IL-22
and its upstream regulator IL-23 are
driven by commensal and pathogenic
microorganisms. In addition, dietary com-
ponents such as cruciferous vegetables
and a high-fat diet can modulate IL-22
expression and, therefore, the interplay
between microbiome and dietary habits
likely has a significant impact on IL-22-
producing cells in CRC. Previous gas-
trointestinal infections leave long-lived
memory T cells specific not only to the
pathogen itself but also to microbiota
(Hand et al., 2012). Presumably, such
history of infections would not only
influence IL-22 expression at any given
time later but also would have a tremen-
dous impact on whether the majority of
helper T cells in the intestine and in CRC
tumors are differentiated towards more
protumorigenic Th22 (and Th17) or, for
example, towards more anticancerous
Th1 lineages.
Overall, Kryczek et al. provide an addi-
tional STAT3-dependent mechanism of
CRC tumor progression, whereby IL-22
drives the expression of the components
of histone methylation machinery and
activation of key cancer stem cell genes
(Figure 1). Whether this phenomenon
has its functional counterpart in the gut
under homeostatic or inflamed conditions
remains to be determined; deletion of
DOT1L in intestinal stem or epithelialImmunitycells increased basal levels of apoptosis
but otherwise had no phenotype (Ho
et al., 2013), similarly to IL-22 deficiency
in normal gut. However, in cancer, epige-
netic regulation of CRC cell ‘‘stemness’’
now finds its place along with well-
characterized features of IL-22-STAT3
pathway in protection of epithelial barriers
and activation of genes responsible for
the resistance to apoptosis and increased
cell proliferation during inflammation and
tumor development.REFERENCES
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